- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin, Lenalidomide, Dexamethasone, Bortezomib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Atlanta, Georgia + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–45
of 21
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab, Carfilzomib, Maplirpacept
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 31
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Encino, California + 15 more
- Conditions
- Multiple Myeloma
- Interventions
- Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more
- Conditions
- Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Interventions
- TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 9 more
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Interventions
- BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- mezigdomide, Pomalidomide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 810 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 56
- States / cities
- Los Alamitos, California • San Diego, California • West Hollywood, California + 50 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- SAR442085
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 5
- States / cities
- Duarte, California • Boston, Massachusetts • Rochester, Minnesota + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- JNJ-79635322
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 23 more
- Conditions
- Plasma Cell Myeloma Recurrent
- Interventions
- Isatuximab IV, Isatuximab SC, Dexamethasone, Pomalidomide, Montelukast, Paracetamol / Acetaminophen, Diphenhydramine, Methylprednisolone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 531 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 23
- States / cities
- Bullhead City, Arizona • Prescott Valley, Arizona • Aurora, Colorado + 19 more
- Conditions
- Multiple Myeloma
- Interventions
- CC-92480, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib, Elotuzumab, Isatuximab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 16
- States / cities
- Denver, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more
- Conditions
- Multiple Myeloma
- Interventions
- Melflufen, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Oncopeptides AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 495 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Fresno, California • Gainesville, Florida + 11 more
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- West Palm Beach, Florida • Kansas City, Missouri • New York, New York + 3 more
- Conditions
- Multiple Myeloma
- Interventions
- Vactosertib, Pomalidomide
- Drug
- Lead sponsor
- Koen van Besien
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fort Collins, Colorado + 20 more
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- Isatuximab SC-OBDS, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Mezigdomide, Carfilzomib, Dexamethasone
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 34
- States / cities
- Mobile, Alabama • Cerritos, California • Irvine, California + 29 more
- Conditions
- Multiple Myeloma
- Interventions
- Cyclophosphamide, Ixazomib, Dexamethasone
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 6
- States / cities
- Hazard, Kentucky • Boston, Massachusetts • Rochester, Minnesota + 3 more
- Conditions
- Multiple Myeloma, Relapse, Refractory, Aging, Co-morbidity
- Interventions
- Isatuximab, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Winston-Salem, North Carolina
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- isatuximab SAR650984, Pomalidomide, Dexamethasone, Carfilzomib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Fullerton, California • San Francisco, California + 21 more
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Interventions
- 18F-fluciclovine injection, 18F-FDG PET/CT
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland